Ftse Mib
34.169,66
0,05%
DAX
18.658,48
0,92%
S&P 500
5.188,36
0,01%
NASDAQ
16.293,22
-0,06%
Bitcoin
61.096,31
-0,15%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND) Notizie

Ascendis Pharma AS

ASND
133,70
-0,23 (-0,17%)
Ultimo aggiornamento: 15:40:31
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/5/202414:30GLOBELatest Clinical and Quality-of-Life Data for TransCon™ PTH..
02/5/202422:01GLOBEAscendis Pharma Reports First Quarter 2024 Financial Results
25/4/202422:46GLOBEAscendis Pharma to Report First Quarter 2024 Financial..
24/4/202414:30GLOBEUnited Kingdom’s MHRA Approves YORVIPATH®..
07/3/202417:31EDGAR2Form 144 - Report of proposed sale of securities
06/3/202403:39EDGAR2Form 144 - Report of proposed sale of securities
05/3/202414:14EDGAR2Form 144 - Report of proposed sale of securities
05/3/202414:04EDGAR2Form 144 - Report of proposed sale of securities
05/3/202413:37EDGAR2Form 144 - Report of proposed sale of securities
04/3/202421:17EDGAR2Form 144 - Report of proposed sale of securities
04/3/202421:07EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:54EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:36EDGAR2Form 144 - Report of proposed sale of securities
04/3/202414:30GLOBEAscendis Pharma to Participate in the Leerink Partners..
01/3/202417:00EDGAR2Form 144 - Report of proposed sale of securities
29/2/202423:13EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:49EDGAR2Form 144 - Report of proposed sale of securities
27/2/202423:45EDGAR2Form 144 - Report of proposed sale of securities
21/2/202421:17EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:16EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:15EDGAR2Form 144 - Report of proposed sale of securities
16/2/202423:14EDGAR2Form 144 - Report of proposed sale of securities
14/2/202422:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/2/202417:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:15EDGAR2Form 20-F - Annual and transition report of foreign private..
07/2/202422:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202422:01GLOBEAscendis Pharma Reports Fourth Quarter and Full Year 2023..
07/2/202414:30GLOBEAscendis Pharma to Participate in the Oppenheimer 34th..
31/1/202422:15GLOBEAscendis Pharma to Report Full Year 2023 Financial Results..
31/1/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/1/202422:01GLOBEAscendis Pharma Launches 2nd TransCon™ Product: YORVIPATH®..
29/1/202414:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/1/202414:30GLOBENew Company Eyconis Formed to Develop Ascendis Pharma..
10/1/202422:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202414:20GLOBEVector Pharma FZCO Announce Exclusive Distribution Agreement..
08/1/202412:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/1/202423:45GLOBEAscendis Pharma Introduces Vision 2030
07/1/202420:00PRNUSSpecialised Therapeutics signs exclusive agreement with..
02/1/202412:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/12/202322:15GLOBEAscendis Pharma to Participate in the 42nd Annual J.P...
20/12/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202314:30GLOBESignificant Health and Quality of Life Improvements Achieved..
19/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/12/202314:30GLOBETransCon™ hGH (lonapegsomatropin) Achieved Statistically..
13/12/202322:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:30GLOBEFDA Accepts for Review Resubmitted NDA for TransCon PTH..
07/12/202320:53EDGAR2Form 144 - Report of proposed sale of securities
Apertura: 134,80 Min: 133,55 Max: 134,80
Chiusura: 133,93

La tua Cronologia

NASDAQ
ASND
Ascendis Pharma AS
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network